Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels | Haematologica
![PDF) Poor performance of the total kappa/lambda light chain quantification in the diagnosis and follow-up of patients with multiple myeloma PDF) Poor performance of the total kappa/lambda light chain quantification in the diagnosis and follow-up of patients with multiple myeloma](https://i1.rgstatic.net/publication/272516929_Poor_performance_of_the_total_kappalambda_light_chain_quantification_in_the_diagnosis_and_follow-up_of_patients_with_multiple_myeloma/links/54f1f9900cf2f9e34eff284d/largepreview.png)
PDF) Poor performance of the total kappa/lambda light chain quantification in the diagnosis and follow-up of patients with multiple myeloma
![Proteínas de mieloma IgG2a(Kappa), control de isotipo [UPC 10], MP Biomedicals 1mg; sin etiquetar Controles y patrones de isotipos | Fisher Scientific Proteínas de mieloma IgG2a(Kappa), control de isotipo [UPC 10], MP Biomedicals 1mg; sin etiquetar Controles y patrones de isotipos | Fisher Scientific](https://assets.fishersci.com/TFS-Assets/CCG/product-images/default.jpg-650.jpg)
Proteínas de mieloma IgG2a(Kappa), control de isotipo [UPC 10], MP Biomedicals 1mg; sin etiquetar Controles y patrones de isotipos | Fisher Scientific
![Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum | Nefrología Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum | Nefrología](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/X2013251413053229:12103_16025_52994_en_f2121033.jpg?idApp=UINPBA000064)